ValiRx Plc is an investment holding Company. The Company is engaged in developing technologies and products in oncology therapeutics and diagnostics. The Company focuses on the treatment of cancer, specialising in epigenomic and genetic analysis. Its technologies and products are also applied to other fields, such as neurology and inflammatory diseases. The Company operates in two segments: drug development and the sale of self-test drug kits. The Company is also engaged in developing a groundbreaking class of therapeutics based on the GeneICE platform and hypergenomics technology. Its VAL201 treats hormone induced refractory prostate cancer and other conditions of hormone induced uncontrolled cell growth including breast and ovarian cancer, among others.